The launch of this service is planned for Q2 2025.

Microsatellite instability (MSI) is a genetic alteration associated with specific cancer types and hereditary Lynch syndrome, resulting from the malfunction of a DNA repair system responsible for maintaining genomic integrity. Determining MSI status is particularly crucial when considering immunotherapy with immune checkpoint inhibitors – a treatment that blocks regulatory points in the immune system – following a clinical cancer diagnosis.

In accordance with the European Society for Medical Oncology (ESMO) recommendations, and as a complement to commonly used immunohistochemical tests, our laboratory assesses MSI status using a multiplex PCR-based method optimized for diagnostic applications. This method is regarded as the gold standard in clinical research.

For more details about our testing portfolio, please feel free to contact us.

Email: seq.acf@med.u-szeged.hu